The margin for rescue recruitment, reforecasting, and preventable dropout is razor thin.Every patient is an investment. Every month matters.Jumo Health adds the readiness layer that helps protect your most important trial.
Biotech operates under constraints that make every trial decision higher stakes. Smaller teams mean less internal bandwidth for patient engagement. Tighter budgets mean rescue recruitment is rarely a fallback. Shorter runways mean timeline delays carry board-level consequences. In this environment, a readiness layer is not overhead. It is the highest-leverage investment available.
One or two assets in the pipeline. When the pipeline is the company, every enrolled patient carries weight that large pharma portfolios can absorb across programs. Biotech teams feel each one.
Board milestones are real. Every month of delay has a capital cost. When the next funding round depends on data readout timing, enrollment reforecasting becomes a board conversation, not just an ops meeting. Timeline predictability matters at every level.
No second budget cycle for rescue recruitment. The enrollment budget must work the first time. There is no supplemental allocation waiting if the original plan underperforms. Every dollar spent on re-recruiting is a dollar that was supposed to fund something else.
No dedicated patient engagement function. Site burden absorbs what should be upstream preparation. Every hour of site rework is an hour the team does not have. When one person covers three roles, the readiness layer cannot depend on manual effort.
Other companies are developing against the same target. A competitor reaching data readout first changes the commercial landscape. Protecting the trial timeline is not just an operational priority. It is a strategic one.
PRISM was built for exactly this constraint profile. It governs readiness before recruitment spend is committed, prepares patients before site resources are allocated, and detects readiness decay before it becomes dropout. For biotech, this readiness layer helps protect the most important investment the company will make.
Every dollar spent on recruitment produces a higher completion yield. Fewer patients needed to hit enrollment targets. Lower cost per completer. No rescue line item. When the budget has no margin, the readiness layer turns recruitment spend into completion outcomes instead of enrollment numbers that do not hold.
CORE deploys in 6-8 weeks. PRISM diagnostics return in 2-3 weeks. You do not trade speed for quality. The readiness layer accelerates enrollment by reducing screen failure and early withdrawal. Patients who arrive prepared move through the trial faster and stay longer.
Three live indices (PXCI, IEQS, CRI) give real-time trial health visibility. Enrollment curves you can present to the board with confidence, not caveats. Instead of reporting enrollment counts that may not predict completion, report readiness-adjusted projections that reflect where patients actually stand.
In a 60-patient Phase 2, losing 5 patients to preventable dropout is not a statistical footnote. It is 8% of your trial. PRISM treats every patient transition as a governed decision. No patient falls out because the system was not watching.
Large pharma absorbs preventable loss across a portfolio. In biotech, the economics are concentrated. When a single pivotal trial carries the company, the cost of each lost patient compounds beyond direct waste into timeline, capital, and competitive consequences.
Start with 60 enrolled patients. Apply the industry-standard 20% early withdrawal rate. That is 12 patients lost. At an average cost of $60,000 per patient, the direct waste is $720,000.
But for biotech, the direct cost is not the real problem. The hidden costs are worse: a 3-6 month timeline extension to re-recruit, additional fundraising pressure to cover the gap, competitive exposure while the trial stalls, and the possibility that the program gets canceled entirely because the board loses confidence in the enrollment trajectory.
Now consider what a 10% improvement in completion changes. That preserves 6 patients. Six patients who complete the trial instead of dropping out. Six patients who keep the enrollment curve on track, protect the timeline, and potentially save the entire program from reforecasting.
For biotech, readiness governance is not an added cost. It is how the existing budget delivers more completers per dollar.
Biotech trials need speed and precision. Both paths are designed for rapid deployment. Choose based on whether your primary gap is operational governance or the combination of education and governance.
CORE educational content deploys in 6-8 weeks. PRISM readiness diagnostics (Baseline TRI, Readiness Friction Map, Readiness Execution Blueprint) return initial findings in 2-3 weeks. For biotech companies operating against investor timelines, the system is designed for rapid deployment without a lengthy evaluation phase. Most biotech engagements move from first conversation to active deployment in under 10 weeks.
Jumo Health structures biotech engagements for capital efficiency. The question is not whether readiness governance fits the budget. It is whether the budget can absorb the cost of not having it. In a 60-patient Phase 2 trial, losing 12 patients to preventable dropout costs approximately $720,000 in direct waste and potentially months of timeline extension. Engagements are scoped to the specific trial, not to an enterprise portfolio, and priced accordingly.
Jumo Health operates as a readiness governance layer alongside your CRO, not in place of it. CROs manage trial operations, site activation, and data collection. Jumo Health governs the patient readiness dimension that CROs are not structured to address. PRISM integrates with existing CRO workflows, and CORE educational content deploys through existing site infrastructure. There is no workflow disruption and no conflict with your CRO scope of work.
Yes. First-in-human studies have some of the highest readiness demands in clinical development. Patients face unfamiliar procedures, uncertain efficacy, and elevated safety monitoring requirements. PRISM adapts its readiness governance to the specific protocol demands and patient population characteristics of early-phase studies. The smaller patient populations in Phase 1 make every individual completion even more statistically significant, which is exactly the scenario where readiness governance has the highest per-patient value.
Protocol amendments are one of the highest-risk moments for patient readiness. Patients who were prepared for the original protocol may not be prepared for the amended version. PRISM detects the readiness impact of amendments and triggers recalibration of educational content, site communication, and patient engagement sequences. CORE content is updated to reflect protocol changes and redeployed through existing channels. The readiness layer adapts to the amendment rather than requiring a manual reset.
PRISM provides three live indices (PXCI, IEQS, CRI) that give real-time visibility into trial health beyond basic enrollment counts. Instead of reporting enrollment numbers that may not predict completion, biotech teams can present readiness-adjusted projections that reflect actual patient preparedness and likelihood of completion. This transforms board updates from enrollment curve presentations into evidence-based trial health reports that investors and board members can evaluate with confidence.
In two days, you get three execution diagnostics on your program.
How likely each eligible patient cluster is to activate, persist, and complete, before any intervention.
The barriers most likely to suppress activation, enrollment, and completion in each cluster, and how to mitigate them.
Which clusters to target, which barriers to address, which interventions to deploy, and what completion lift to expect.